tiprankstipranks
Mckesson Corp. (MCK)
NYSE:MCK
Holding MCK?
Track your performance easily

McKesson (MCK) Stock Price & Analysis

1,856 Followers

MCK Stock Chart & Stats


Bulls Say, Bears Say

Bulls Say
Acquisition ImpactThe pending acquisition of Florida Cancer Specialists is expected to bolster McKesson's oncology franchise by adding 500+ providers at approximately 100 care sites in Florida.
Financial PerformanceMCK posted an adjusted EPS beat, significantly higher than consensus estimates, indicating strong financial performance.
Oncology PlatformManagement has created a high-value $35 billion oncology platform that should allow for greater-than-average visibility on McKesson's ability to generate 12-14% EPS growth over the long term, which is above peers.
Bears Say
Revenue GuidanceThe company reduced its revenue guidance in its Med-Surg business, pointing to normalization of market conditions and lower volumes.
Segment PerformanceMedical AOI deteriorated 4.3% year over year attributable to lower volumes and customer mix.
Stock PerformanceNear-term upside for McKesson shares may be limited due to the 30% rally over the past few months.
---

Financials

Annual

Ownership Overview

0.08%22.50%0.77%56.11%
0.77% Other Institutional Investors
56.11% Public Companies and Individual Investors

Risk Analysis

Main Risk Category
ProductionRisks related to the company’s ability to manufacture goods and services

Website Traffic

Sorry, No Data Available
There is no website visitor data available for this stock.
---

MCK FAQ

What was Mckesson Corp.’s price range in the past 12 months?
Mckesson Corp. lowest stock price was $464.42 and its highest was $637.51 in the past 12 months.
    What is Mckesson Corp.’s market cap?
    Mckesson Corp.’s market cap is $75.55B.
      When is Mckesson Corp.’s upcoming earnings report date?
      Mckesson Corp.’s upcoming earnings report date is Feb 05, 2025 which is in 18 days.
        How were Mckesson Corp.’s earnings last quarter?
        Mckesson Corp. released its earnings results on Nov 06, 2024. The company reported $7.07 earnings per share for the quarter, beating the consensus estimate of $6.881 by $0.189.
          Is Mckesson Corp. overvalued?
          According to Wall Street analysts Mckesson Corp.’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
            Does Mckesson Corp. pay dividends?
            Mckesson Corp. pays a Quarterly dividend of $2.658 which represents an annual dividend yield of 0.46%. See more information on Mckesson Corp. dividends here
              What is Mckesson Corp.’s EPS estimate?
              Mckesson Corp.’s EPS estimate is 8.23.
                How many shares outstanding does Mckesson Corp. have?
                Mckesson Corp. has 126,940,094 shares outstanding.
                  What happened to Mckesson Corp.’s price movement after its last earnings report?
                  Mckesson Corp. reported an EPS of $7.07 in its last earnings report, beating expectations of $6.881. Following the earnings report the stock price went up 10.594%.
                    Which hedge fund is a major shareholder of Mckesson Corp.?
                    Among the largest hedge funds holding Mckesson Corp.’s share is Brandes Investment Partners LP. It holds Mckesson Corp.’s shares valued at 186M.
                      ---

                      Company Description

                      Mckesson Corp.

                      Incorporated in 1833, Texas-based McKesson Corp. provides pharmaceuticals, health information technology, medical supplies, and care management tools. The company operates through four segments: U.S. Pharmaceutical, Prescription Technology Solutions, International, and Medical-Surgical Solutions.
                      ---

                      MCK Company Deck

                      ---

                      MCK Earnings Call

                      Q2 2024
                      0:00 / 0:00
                      Earnings Call Sentiment|Positive
                      The earnings call presented a strong performance with significant revenue and EPS growth, enhanced shareholder returns, and strategic expansions in oncology and biopharma services. However, some concerns remain about the medical segment's performance and margin pressures from GLP-1 products.Read More>
                      ---

                      MCK Revenue Breakdown

                      90.22%90.22%4.57%3.66%1.54%
                      90.22% U.S. Pharmaceutical
                      4.57% International
                      3.66% Medical-Surgical Solutions
                      1.54% Prescription Technology Solutions
                      tipranks
                      ---

                      MCK Stock 12 Month Forecast

                      Average Price Target

                      $671.00
                      ▲(12.74% Upside)
                      {"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"470":"$470","593":"$593","716":"$716","531.5":"$531.5","654.5":"$654.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":715,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$715.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":671,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$671.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":630,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$630.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[470,531.5,593,654.5,716],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Apr<br/>2024","6":"Jul<br/>2024","9":"Oct<br/>2024","12":"Jan<br/>2025","25":"Jan<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,569.91,581.0707692307692,592.2315384615384,603.3923076923077,614.5530769230769,625.7138461538461,636.8746153846154,648.0353846153846,659.1961538461538,670.3569230769231,681.5176923076923,692.6784615384615,703.8392307692308,{"y":715,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,569.91,577.6861538461538,585.4623076923077,593.2384615384615,601.0146153846154,608.7907692307692,616.5669230769231,624.3430769230769,632.1192307692307,639.8953846153846,647.6715384615385,655.4476923076923,663.2238461538461,{"y":671,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,569.91,574.5323076923077,579.1546153846153,583.776923076923,588.3992307692307,593.0215384615384,597.6438461538461,602.2661538461539,606.8884615384616,611.5107692307693,616.1330769230769,620.7553846153846,625.3776923076923,{"y":630,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":471.21,"date":1704067200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":499.51,"date":1706745600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":524.04,"date":1709251200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":534.62,"date":1711929600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":529.25,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":567.6,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":584.93,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":627.58,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":560.45,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":497.92,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":525.74,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":621.29,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":569.91,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
                      Similar Stocks
                      Company
                      Price & Change
                      Follow
                      Cardinal Health
                      CVS Health
                      Walgreens Boots Alliance
                      Cigna
                      Humana
                      Thermo Fisher

                      Best Analysts Covering MCK

                      1 Year
                      1 Year Success Rate
                      19/21 ratings generated profit
                      90%
                      1 Year Average Return
                      +30.09%
                      reiterated a buy rating 3 months ago
                      Copying Kevin Caliendo's trades and holding each position for 1 Year would result in 90.48% of your transactions generating a profit, with an average return of +30.09% per trade.
                      Popular Stocks
                      ---
                      What am I Missing?
                      Make informed decisions based on Top Analysts' activity
                      Know what industry insiders are buying
                      Get actionable alerts from top Wall Street Analysts
                      Find out before anyone else which stock is going to shoot up
                      Get powerful stock screeners & detailed portfolio analysis